Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] Clinical Trials
3 recruitingDrug
Phase 42
Showing 1–3 of 3 trials
Recruiting
Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP
Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis Without Nasal Polyps
Medical University of Vienna80 enrolled1 locationNCT06398873
Recruiting
Phase 4
Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
Chronic Rhinosinusitis With Nasal PolypsOlfactory Disorder
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's27 enrolled1 locationNCT04869436
Recruiting
Phase 4
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis (EoE)
University of California, San Diego30 enrolled1 locationNCT06665971